Novartis Trading Volume Surges 106.76% to 347th Position with 3.70 Billion Turnover

On May 12, 2025, Novartis (NVS) saw a significant increase in trading volume, with a turnover of 3.70 billion, marking a 106.76% rise from the previous day. This surge placed Novartis at the 347th position in terms of trading volume for the day. The stock price of Novartis rose by 0.23%.

Novartis is at the forefront of the radiopharmaceuticals market, which is projected to reach $16 billion by 2033. The company is investing heavily in this sector, focusing on new indications and innovative treatments. This strategic move is expected to drive growth and enhance Novartis' market position.

Novartis has recently announced significant investments in U.S. manufacturing, totaling $23 billion over the next five years. This initiative aims to bolster the company's production capabilities and create new job opportunities, aligning with broader industry trends of increased manufacturing investments to mitigate tariff risks.

In a recent acquisition, Novartis has purchased Regulus Therapeutics for up to $1.7 billion. This deal is centered around Regulus' farabursen, an miRNA-targeting oligonucleotide in early-stage development for rare autosomal dominant polycystic kidney disease. This acquisition is part of Novartis' broader strategy to enhance its pipeline and expand its therapeutic offerings.

Novartis' CEO, Vas Narasimhan, has expressed concerns about potential drug pricing controls in the U.S. He stated that if international drug pricing is adopted, it would necessitate a reassessment of the company's medium- to long-term outlook. This statement underscores the regulatory challenges facing the pharmaceutical industry and their potential impact on Novartis' financial performance.